DEADLINE EXTENDED
Give by midnight tonight and your gift will be DOUBLED for kids! For every gift of $35 or more, a special My Paw in Yours Puppy will go to a patient.
Abiraterone Acetate in Children with Classic 21-Hydroxylase Deficiency
A Phase 1-2 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children with Classic 21-Hydroxylase Deficiency
(1) determine the minimum effective dose of abiraterone acetate that normalizes androstenedione levels in prepubertal children with CAH secondary to 21-hydroxylase deficiency (Phase 1 trial), and (2) assess the utility of abiraterone acetate in prepubertal children with CAH as adjunctive therapy to minimize excessive androgen secretion and allow more physiological glucocorticoid replacement (Phase 2 trial).
CHLA IRB Number
CHLA-17-00283
Eligibility
Males or females 2-9 years of age diagnosed with CAH
Clinical Trials Government Identifier
NCT03548246
Enrollment Status
Open
Does this study also recruit healthy volunteers?
No
Coordinator Contact
Norma Martinez
Contact Email
nzmartinez@chla.usc.edu